☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Uterine fibroids
PharmaShots Interview: Myovant's Dave Marek Shares Insights on the US FDA's Approval of Myfembree in Uterine Fibroids
July 20, 2021
Myovant's Ryeqo (relugolix- estradiol- and norethindrone acetate) Receives EC's Approval for the Treatment of Women with Uterine F...
July 20, 2021
Pfizer and Myovant's Myfembree Receive the US FDA's Approval for Heavy Menstrual Bleeding Associated with Uterine Fibroids
May 27, 2021
Pfizer and Myovant Report Results of Relugolix Combination Therapy in P-III LIBERTY Withdrawal Study in Women with Uterine Fibroid...
March 25, 2021
Myovant and Pfizer Publish the Results of Relugolix Combination Regimen in P-III LIBERTY Studies in NEJM
February 18, 2021
AbbVie and Neurocrine's Oriahnn Receive the US FDA's Approval as the First Oral Therapy for the Management of Heavy Menstrual Blee...
May 29, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.